Your session is about to expire
← Back to Search
Cabozantinib + Pamiparib for Advanced Cancer
Study Summary
This trial finds the best dose and side effects of cabozantinib and pamiparib in treating patients with advanced or refractory solid tumors.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 45 Patients • NCT02101736Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My condition has a specific genetic feature confirmed by a certified lab.I have not received a live vaccine recently.I am currently taking blood thinners.I have brain metastases or cranial epidural disease.I do not have any serious wounds, thyroid issues, or severe liver problems.My cancer can be measured or seen on scans, and I have at least one tumor that can be biopsied.I can take pills and do not have chronic stomach or absorption problems.I am on treatment for HIV or have active hepatitis B or C.My cancer has spread to major blood vessels or specific areas in my lungs.I am 18 years old or older.I am currently receiving treatment for cancer.I agree to use effective birth control during and 6 months after the study.I have not had significant bleeding or blood in my urine, vomit, or cough.I have recently undergone radiation therapy or treatment with radioactive substances.I am fully active or restricted in physically strenuous activity but can do light work.I am willing to provide tissue samples for the study.I have heart problems or recent blood clot issues.I have had surgery recently.I am not currently receiving any other cancer treatments.I have recently received treatment for my cancer.I have at least one tumor that can be measured and another that can be biopsied.I am not taking any drugs that strongly affect liver enzymes.My liver and kidney functions meet the required levels.I have moderate to severe numbness, tingling, or pain in my hands or feet.I have a serious gut condition that could lead to complications.I have not been treated with drugs that target PARP and VEGF at the same time.I agree to use effective birth control methods.My cancer can be measured or seen on scans.I am 18 years old or older.My advanced cancer does not respond to standard treatments, or there are none, or I chose not to use them.I haven't had radiation aimed at relieving symptoms on my only cancer spots during the study.I do not have a serious infection or condition that could interfere with treatment.I still have side effects from previous treatments.I cannot swallow pills.
- Group 1: Treatment (cabozantinib, pamiparib)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Have any other research projects explored the effects of Cabozantinib?
"Currently, there are 118 active studies on Cabozantinib with 12 at Phase 3. While concentrated in Cordoba and Calabria, over 7000 different clinical sites around the world are conducting trials revolving around this drug."
Are there any slots remaining for participation in this trial?
"As confirmed on the clinicaltrials.gov website, this medical trial is in progress. It was initially advertised to the public on February 9th 2022 and has been edited as recently as July 31st of that same year."
For what medical conditions is Cabozantinib commonly prescribed?
"Cabozantinib is usually prescribed as a follow up to anti-VEGF therapy. It also has been found useful in treating advanced renal cell carcinoma (ARCC) and adrenal medulla for high risk patients."
Could you elucidate on the safety profile of Cabozantinib?
"Due to the preliminary nature of this clinical trial, cabozantinib's safety rating is a 1 on our scale. This score reflects the fact that we have limited data regarding its efficacy and security."
Is this an unprecedented examination?
"Since its first research trial in 2012, sponsored by Exelixis and involving 86 participants, Cabozantinib has been thoroughly studied. It was subsequently approved for Phase 2 drug trials and is presently the subject of 118 studies spanning 1370 cities and 45 countries worldwide."
What is the size of the cohort involved in this trial?
"Affirmative. Clinicaltrials.gov reveals that this experiment, which was initially advertised on February 9th 2022, is currently searching for volunteers. 44 participants are necessary from 1 medical facility."
Who else is applying?
How old are they?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger